Skip to main content

Cyclooxygenase inhibitors: any reservations?

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Abstract

The discovery of two cyclooxygenase isozymes, constitutive COX-1 and inducible COX-2, has resulted in the rapid development of selective inhibitors of COX-2, such as celecoxib and rofecoxib. Compared with traditional non-steroidal anti-inflammatory drug agents, use of COX-2 selective inhibitors is associated with decreased incidence of adverse gastric events as a result of minimal inhibition of gastroprotective COX-1, but with equivalent anti-inflammatory benefit through inhibition of COX-2. However, there is evidence to suggest that the ‘COX-1 = constitutive, COX-2 = inflammatory’ paradigm is less distinct than originally proposed. Futhermore, selective COX-2 inhibitors may have other consequences as a result of the change in the eicosanoid profile. Thus, despite the relatively safe gastrointestinal profile, vigilant post-marketing surveillance for other adverse effects is required. (Intern Med J 2001; 31: 37–41.

Keywords: cyclooxygenase; eicosanoid; non-steroidal anti-inflammatory drug; selective

Document Type: Research Article

DOI: http://dx.doi.org/10.1046/j.1445-5994.2001.00002.x

Publication date: January 1, 2001

bsc/imj/2001/00000031/00000001/art00008
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more